Zentalis Pharmaceuticals is based in New York. It has raised $147M in total funding. Latest round: IPO.
Zentalis Pharmaceuticals funding overview
Zentalis Pharmaceuticals is based in New York. Zentalis Pharmaceuticals has raised $147M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is an IPO announced in December 2019. The round record for Zentalis Pharmaceuticals runs through 2019; nothing later has been disclosed. Investors on record include Viking Global Investors, Redmile Group, Farallon Capital Management. 3 distinct backers are named across the disclosed rounds.
Zentalis Pharmaceuticals at a glance
Total raised
$147M
Latest round
IPO
Latest round date
December 2019
Headquarters
New York
Notable investors
Viking Global Investors, Redmile Group, Farallon Capital Management
Frequently asked about Zentalis Pharmaceuticals funding
How much has Zentalis Pharmaceuticals raised?
Zentalis Pharmaceuticals has raised $147M in total disclosed funding across the rounds on record.
Who has invested in Zentalis Pharmaceuticals?
Viking Global Investors, Redmile Group, Farallon Capital Management are named among the investors backing Zentalis Pharmaceuticals.
What was the latest Zentalis Pharmaceuticals funding round?
The most recent disclosed round is an IPO, announced in December 2019.
Where is Zentalis Pharmaceuticals based?
Zentalis Pharmaceuticals is based in New York.
When did Zentalis Pharmaceuticals last raise?
The last disclosed Zentalis Pharmaceuticals round closed in December 2019 at IPO.
Zentalis Pharmaceuticals totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in New York below to benchmark round size and investor mix.
Companies related to Zentalis Pharmaceuticals (35)
